NCT06144151 A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
| NCT ID | NCT06144151 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Neurotoxicity |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-02-08 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-02-08 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To learn about the relationship between changes in pupil size and reactivity and the start of neurological side effects in patients after receiving CAR-T cell therapy.
Eligibility Criteria
Inclusion Criteria: To be considered eligible for study participation, patient will satisfy all relevant inclusion criteria and none of the exclusion criteria. Inclusion Criteria: 1. Ages Eligible for Study: 18 Years and above (Adult, Older Adult) 2. Sexes Eligible for Study: All 3. Patient with histologically proven DLBCL, PMBCL or tFL, or follicular Lymphoma receiving axi-cel CAR-T cell therapy in the inpatient setting at MD Anderson Cancer Center 4. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Patients who have already been administered CAR-T cell therapy. 2. The patient who is unwilling or unable to comply with the requirements of the study including being able to be assessed with pupillometer 3. Patient has a condition which places him at an unacceptable risk as determined by the investigator
Contact & Investigator
Ranjit Nair, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT06144151 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neurotoxicity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06144151 currently recruiting?
Yes, NCT06144151 is actively recruiting participants. Contact the research team at rnair@mdanderson.org for enrollment information.
Where is the NCT06144151 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06144151 clinical trial?
NCT06144151 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Ranjit Nair, MD at M.D. Anderson Cancer Center. The trial plans to enroll 100 participants.